Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction

Miracor Medical SA145 enrolled

Overview

The objective of this study is to assess efficacy and safety of Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) therapy started post flow restoration but prior to stenting during percutaneous coronary intervention (PCI) compared to standard PCI in the setting of acute ST-segment elevation anterior myocardial infarction (STEMI).

This is a prospective, multicenter, randomized (1:1), controlled, study. Patients with an ST-segment elevated anterior infarct eligible for PCI will be invited to participate in the PiCSO-AMI-I study. After consent as per pproved ethics committee requirements, baseline assessments will be performed. PCI of the culprit vessel should be performed per standard practices. After blood flow restoration, the subjects meeting all inclusion and none exclusion criterial will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. In the event the PiCSO Impulse Catheter cannot be placed in the CS within 30 minutes, the physician should proceed with the regular PCI and the PiCSO treatment will be considered a failure. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes (at minimum 30 minutes) whereas the treatment should be continued during and post stent insertion, but should not exceed a maximum duration of 90 minutes. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed. The patient is seen for a FU visit at 5 days, 30 days, 6 months, 1 year, 2 year and 3 years post index procedure. 5 days and 6 months post index the patient will get a CMR scan. At every FU visit safety data and health status will be documented and quality of life questionnaire will be completed.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

145

Conditions

STEMI Anterior MI

Interventions

PiCSODEVICE

After blood flow restoration, the subjects meeting all inclusion and none exclusion criterial will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes (at minimum 30 minutes) whereas the treatment should be continued during and post stent insertion, but should not exceed a maximum duration of 90 minutes. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age ≥18 years old 2. Culprit lesion in proximal or mid LAD 3. Pre-PCI TIMI flow 0 or 1. 4. Symptoms onset time consistent with myocardial ischemia (e.g. persistent chest pain, shortness of breath, nausea/vomiting, fatigue, palpitations or syncope) ≤ 12 h. 5. ECG evidence of acute anterior myocardial infarction with ST-elevation ≥ 2 mm (0.2 mV) in 2 or more contiguous anterior precordial ECG leads (one of which should be V2, V3, or V4) in men or ≥ 1.5 mm (0.15 mV) in women 6. Patient is deemed eligible for primary PCI 7. STEMI patients: consent as per approved national ethical committee specific requirements prior to the procedure. Exclusion criteria: 1. Implants or foreign bodies in the coronary sinus 2. Known allergy to polyurethanes, PET or stainless steel 3. Known pregnancy and breastfeeding 4. Pericardial effusion (cardiac tamponade) 5. Central hemodynamically relevant left/right shunt 6. Previous MI or CABG 7. History of stroke, TIA or reversible ischemic neurological deficit within last 6 months 8. Known coagulopathy 9. Need for circulatory support or pre-procedural ventilation 10. Patients with cardio-pulmonary resuscitated (CPR) cardiac arrest for more than 5 minutes 11. Patient not suitable for femoral vein access 12. Contraindication to cardiac magnetic resonance imaging (CMR), e.g. claustrophobia, foreign body implants incompatible with CMR, gadolinium intolerance. 13. Active participation in another drug or device investigational study 14. Known severe kidney disease or on hemodialysis 15. Unconscious on presentation 16. Patients under judicial protection, legal guardianship or curatorship

Locations (17)

Aarhus Universitetshospital

Aarhus, Denmark

Odense University Hospital

Odense, Denmark

Outcomes

Primary Outcomes

Infarct size 5 days post MI

Difference in myocardial infarct size (extent of myocardial necrosis quantified by delayed gadolinium enhancement presented as a percentage of LV mass) between the PiCSO Group and the Control Group, assessed by CMR at 5 days post index PCI

Time frame: 5 days post MI

Secondary Outcomes

Infarct size 6 months post MI

Myocardial infarct size (% of LV mass) assessed by CMR at 6 months post index PCI

Time frame: 6 months post MI

MVO

Occurrence and extent of microvascular obstruction (MVO, % of LV mass) and hemorrhage assessed by CMR at 5 days post index PCI

Time frame: 5 days post MI

LVEF

LVEF assessed by CMR at 5 days and 6 months post index PCI

Time frame: 5 days and 6 months post MI

LVESV

LVESV assessed by CMR at 5 days and 6 months post index PCI

Time frame: 5 days and 6 months post MI

LVEDV

LVEDV assessed by CMR at 5 days and 6 months post index PCI

Time frame: 5 days and 6 months post MI

Myocardial Salvage

Myocardial Salvage Index at 5 days and 6 month post index PCI

Time frame: 5 days and 6 months post MI

ST-segment resolution

ST-segment resolution at 90 minutes post flow restoration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.